{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:21:21Z","timestamp":1761517281242,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1996,1,1]],"date-time":"1996-01-01T00:00:00Z","timestamp":820454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1996,1,1]],"date-time":"1996-01-01T00:00:00Z","timestamp":820454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[1996,1]]},"DOI":"10.4158\/ep.2.1.30","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:23:44Z","timestamp":1365204224000},"page":"30-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Dyslipidemias"],"prefix":"10.1016","volume":"2","author":[{"given":"Peter H.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.2.1.30_bb0005","first-page":"1344","article-title":"Evaluation and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel II","volume":"89","author":"Report of the National Cholesterol Education Program Expert Panel on Detection","year":"1994","journal-title":"Circulation."},{"key":"10.4158\/EP.2.1.30_bb0010","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease","volume":"251","author":"Lipid Research Clinics Program","year":"1984","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0015","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.2.1.30_bb0020","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0025","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipolniacin on coronary atherosclerosis: a 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0030","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.2.1.30_bb0035","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.2.1.30_bb0040","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0045","first-page":"129","article-title":"Can lifestyle changes reverse coronary heart disease?","volume":"336","author":"Ornish","year":"1990","journal-title":"The Lifestyle Heart Trial. Lancet."},{"key":"10.4158\/EP.2.1.30_bb0050","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0140-6736(92)90863-X","article-title":"Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas\u2019 Atherosclerosis Regression Study (STARS)","volume":"339","author":"Watts","year":"1992","journal-title":"Lancet."},{"key":"10.4158\/EP.2.1.30_bb0055","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-119-10-199311150-00002","article-title":"Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS)","volume":"119","author":"Blankenhorn","year":"1993","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.2.1.30_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science."},{"key":"10.4158\/EP.2.1.30_bb0065","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.aje.a115704","article-title":"Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease","volume":"132","author":"Berlin","year":"1990","journal-title":"Am J Epidemiol."},{"key":"10.4158\/EP.2.1.30_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.89.6.2540","article-title":"Physical activity and 23 year incidence of coronary heart disease morbidity and mortality among middle-aged men: The Honolulu Heart Program","volume":"89","author":"Rodriguez","year":"1994","journal-title":"Circulation."},{"key":"10.4158\/EP.2.1.30_bb0075","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemia subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism."},{"key":"10.4158\/EP.2.1.30_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med."},{"key":"10.4158\/EP.2.1.30_bb0085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"Chinchili VM. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJM198807073190105","article-title":"CoA reductase inhibitors for treatment of hypercholesterolemia","volume":"319","author":"Grundy","year":"1988","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.2.1.30_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00041433-199102000-00006","article-title":"HMG CoA reductase inhibitors","volume":"2","author":"Illingworth","year":"1991","journal-title":"Curr Opin Lipidol."},{"key":"10.4158\/EP.2.1.30_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8,245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP.2.1.30_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy","volume":"264","author":"Pierce","year":"1990","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0110","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. III. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.2.1.30_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/0003-4819-98-5-623","article-title":"Type III hyperlipidemia: diagnosis, molecular defects, pathology and treatment","volume":"98","author":"Brewer","year":"1983","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.2.1.30_bb0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation."},{"key":"10.4158\/EP.2.1.30_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9149(92)91380-M","article-title":"Gemfibrozil-lovastatin therapy for primary hyperlipidemias","volume":"70","author":"Glueck","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP.2.1.30_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9343(93)90114-5","article-title":"Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia","volume":"94","author":"Wiklind","year":"1993","journal-title":"Am J Med."},{"key":"10.4158\/EP.2.1.30_bb0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia","volume":"73","author":"Davignon","year":"1994","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP.2.1.30_bb0140","first-page":"1027","article-title":"The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipidemia","volume":"70","author":"Feussner","year":"1992","journal-title":"J Clin Invest."},{"key":"10.4158\/EP.2.1.30_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.ATV.11.1.2","article-title":"Plasma triglycerides and coronary heart disease","volume":"11","author":"Austin","year":"1991","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10.4158\/EP.2.1.30_bb0150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease (the PROCAM experience)","volume":"70","author":"Assman","year":"1992","journal-title":"Am J Cardiol."},{"key":"10.4158\/EP.2.1.30_bb0155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.1993.tb35689.x","article-title":"-3 fatty acids from fish oil-effects on plasma lipoproteins and hypertriglyceridemic patients","volume":"683","author":"Connor","year":"1993","journal-title":"Ann N Y Acad Sci."},{"key":"10.4158\/EP.2.1.30_bb0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jama.1994.03510370051031","article-title":"Lipoprotein (a) levels and risk of coronary heart disease in men: The Lipid Research Clinics Coronary Primary Prevention Trial","volume":"271","author":"Schaefer","year":"1994","journal-title":"JAMA."},{"key":"10.4158\/EP.2.1.30_bb0165","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.1993.03510180065035","article-title":"Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction","volume":"270","author":"Ridker","year":"1993","journal-title":"JAMA."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/XY31KC5EBNYUY7W2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:16:17Z","timestamp":1761516977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20412662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1996,1]]}},"alternative-id":["S1530891X20412662"],"URL":"https:\/\/doi.org\/10.4158\/ep.2.1.30","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[1996,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Dyslipidemias","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.2.1.30","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1996 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}